ProShare Advisors LLC Sells 1,970 Shares of Apogee Therapeutics Inc. $APGE

ProShare Advisors LLC trimmed its holdings in shares of Apogee Therapeutics Inc. (NASDAQ:APGE) by 19.2% in the second quarter, HoldingsChannel reports. The firm owned 8,265 shares of the company’s stock after selling 1,970 shares during the period. ProShare Advisors LLC’s holdings in Apogee Therapeutics were worth $359,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Victory Capital Management Inc. grew its holdings in shares of Apogee Therapeutics by 4.4% during the first quarter. Victory Capital Management Inc. now owns 232,983 shares of the company’s stock worth $8,704,000 after purchasing an additional 9,921 shares during the last quarter. XTX Topco Ltd lifted its position in Apogee Therapeutics by 170.8% during the 1st quarter. XTX Topco Ltd now owns 17,188 shares of the company’s stock worth $642,000 after buying an additional 10,840 shares in the last quarter. Invesco Ltd. grew its holdings in Apogee Therapeutics by 14.4% during the 1st quarter. Invesco Ltd. now owns 24,310 shares of the company’s stock worth $908,000 after acquiring an additional 3,054 shares during the last quarter. Nuveen LLC acquired a new stake in Apogee Therapeutics in the 1st quarter valued at about $4,142,000. Finally, Brooklyn Investment Group bought a new position in shares of Apogee Therapeutics in the first quarter worth about $42,000. Institutional investors and hedge funds own 79.04% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently commented on APGE shares. BTIG Research reissued a “buy” rating and set a $115.00 price target on shares of Apogee Therapeutics in a research note on Thursday, October 9th. Bank of America upped their price objective on Apogee Therapeutics from $78.00 to $87.00 and gave the stock a “buy” rating in a report on Thursday, August 28th. Royal Bank Of Canada lifted their target price on Apogee Therapeutics from $60.00 to $70.00 and gave the company an “outperform” rating in a research note on Monday, November 3rd. Wall Street Zen upgraded Apogee Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. Finally, Citigroup reiterated a “buy” rating on shares of Apogee Therapeutics in a report on Thursday, August 28th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $96.50.

Insider Transactions at Apogee Therapeutics

In related news, CEO Michael Thomas Henderson sold 20,000 shares of the stock in a transaction that occurred on Thursday, November 13th. The shares were sold at an average price of $63.01, for a total value of $1,260,200.00. Following the sale, the chief executive officer directly owned 1,272,987 shares in the company, valued at $80,210,910.87. This trade represents a 1.55% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Carl Dambkowski sold 10,785 shares of Apogee Therapeutics stock in a transaction that occurred on Wednesday, November 5th. The stock was sold at an average price of $55.07, for a total transaction of $593,929.95. Following the transaction, the insider directly owned 282,008 shares in the company, valued at $15,530,180.56. The trade was a 3.68% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 38,620 shares of company stock worth $2,160,704. Company insiders own 42.77% of the company’s stock.

Apogee Therapeutics Stock Performance

APGE opened at $66.26 on Friday. The company has a fifty day moving average price of $50.79 and a two-hundred day moving average price of $43.14. The firm has a market capitalization of $4.53 billion, a PE ratio of -15.13 and a beta of 1.50. Apogee Therapeutics Inc. has a 52 week low of $26.20 and a 52 week high of $67.66.

Apogee Therapeutics (NASDAQ:APGE) last posted its quarterly earnings results on Monday, November 10th. The company reported ($1.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.14) by $0.03. Equities analysts forecast that Apogee Therapeutics Inc. will post -3.09 EPS for the current year.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.